Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05086549
Other study ID # BR-FMS-OS-407
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 29, 2021
Est. completion date June 5, 2023

Study information

Verified date July 2023
Source Boryung Pharmaceutical Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who are given antihypertensives containing fimasartan, in an actual clinical environment where a variety of patient characteristics are reflected.


Description:

This prospective observational study is conducted in about 5 medical institutions located in Korea, which are equal to or larger than a hospital, and patients with type 2 diabetic kidney disease (proteinuria with an ACR of 10 mg/g or higher), who are being administered or plan to be administered with antihypertensives containing fimasartan for essential hypertension, are enrolled as the subjects. Each of the subjects shall undergo follow-up for about a year (52 weeks). After explaining the purpose, method, scope of information to be collected, and procedure of this study to potential subjects, the investigator shall obtain the written consent for voluntary participation and set the day when the antihypertensive containing fimasartan is administered as the baseline. If the fimasartan-based antihypertensive treatment is already ongoing, only the patients within 6 weeks from the baseline shall be considered as the subjects. In this case, data from between the baseline and the time of the written consent shall be collected retrospectively. This study is an observational study, and the drugs which are administered during the study period and the medical procedures shall be in accordance with the clinical judgment of the investigator. It is a rule that no unnecessary intervention shall be imposed on the subjects by this study protocol. The scope of data to be collected during this study period is as follows. - Demographic information - Disease information (diabetes, hypertension, renal disease, other past medical history and intercurrent diseases) - Physical measurements (height and weight) - Clinic blood pressure measurements - Laboratory test results - Antihypertensives, hypoglycemic agents, and other concomitant drugs - Fimasartan-related adverse drug reactions and serious adverse drug reactions - Death information (if applicable)


Recruitment information / eligibility

Status Completed
Enrollment 360
Est. completion date June 5, 2023
Est. primary completion date June 5, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Male and female adults aged 19 or older - Those who were diagnosed with type 2 diabetes and have been being given stable doses of hypoglycemic agents for 8 weeks or longer - Those in whom albuminuria was found to meet one of the following criteria two times before the administration of the antihypertensive treatment containing fimasartan (results (baseline values) within 4 weeks before the administration of antihypertensives must be ACR or AER results) - An albumin/creatinine ratio (ACR) of 10 mg/g or higher or - An albumin excretion rate (AER) of 10 mg/day or higher or - A proteinuria/creatinine ratio (PCR) of 70 mg/g or higher or - A urine dipstick result of trace to 1+ or higher - Those who plan to be given antihypertensive treatment containing fimasartan for essential hypertension or are being given the treatment (in this case, those with an administration period of 6 weeks or lower can be enrolled) - Those with records of clinical systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 85 mmHg or higher before the antihypertensive treatment containing fimasartan or at the time of the treatment. The following additional criteria shall be applied depending on age and the presence of comorbidities. - Aged younger than 65: Systolic blood pressure of 130 mmHg or higher or diastolic blood pressure of 80 mmHg or higher shall be applied to those with cardiovascular disease or an ACR or AER of 30 mg/g or higher. - Aged 65 or older: Regardless of comorbidities, systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90 mmHg or higher shall be applied. - Patients who agreed in writing to the Personal Information Collection and Usage Agreement after listening to the explanation of the objective, method, etc. of this observational study Exclusion Criteria: - Patients who are suspected of or confirmed with secondary hypertension - Those diagnosed with type 1 diabetes or secondary diabetes - Patients undergoing kidney dialysis or patients who received kidney transplants or those for whom kidney dialysis or kidney transplants are planned - If angiotensin converting enzyme inhibitors (ACEI) or renin inhibitors are used in conjunction or are planned to be used in conjunction - Patients with moderate to severe hepatic dysfunction (ALT and/or AST of over three times the upper limit of normal) or patients with biliary tract obstruction - Pregnant and breast-feeding women - Those who were administered with drugs for clinical studies within 12 weeks from the enrollment or those who plan on participating in other clinical studies while participating in this study - Other subjects who are considered inappropriate to participate in the study by the investigator's decision

Study Design


Locations

Country Name City State
Korea, Republic of Severance hospital, Yonsei University Health System Seoul

Sponsors (1)

Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of change in albuminuria (urine ACR) The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the rate of change in albuminuria (urine ACR) at the baseline, on Week 8, and on Week 8 compared to the baseline shall be obtained Week 8
Secondary Quantity of change in albuminuria (urine ACR) The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the quantity of change in albuminuria (urine ACR) at the baseline, on Week 8, and on Week 8 compared to the baseline shall be obtained Week 8
Secondary Rate of change in albuminuria (urine ACR) The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the rate of change in albuminuria (urine ACR) at each time point, on Week 26 and Week 52 compared to the baseline shall be obtained Week 26, Week 52
Secondary Rate of change in proteinuria (urine PCR) The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the rate of change in proteinuria (urine PCR) at each time point, on Week 8, Week 26, and Week 52 compared to the baseline shall be obtained Week 8, Week 26, Week 52
See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Terminated NCT04051957 - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Phase 2
Terminated NCT02057523 - Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Phase 4
Completed NCT02232763 - Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria Phase 3
Completed NCT02226055 - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka N/A
Completed NCT00493727 - Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria N/A
Active, not recruiting NCT00565396 - Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Withdrawn NCT02882373 - Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury Phase 2
Completed NCT02327403 - Belatacept Conversion in Proteinuric Kidney Transplant Recipients Phase 2
Recruiting NCT01773382 - The Effects of Weight Reduction in IgA Nephropathy N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT01029002 - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease Phase 3
Withdrawn NCT00541619 - Sympathetic Overactivity in Essential Hypertension N/A
Withdrawn NCT00392132 - Impact of Screening Patients With HIV for Kidney Disease
Terminated NCT00001978 - Determination of Kidney Function
Recruiting NCT05457283 - A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Phase 3
Completed NCT04874753 - The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
Recruiting NCT02972346 - Availability Study of ACTH to Treat Children SRNS/SDNS N/A
Unknown status NCT02256995 - uChek Pilot Study for Urinalysis in the Antenatal Care Setting N/A